Table 5 Multivariate analysis of recurrence-free survival and tumor budding using ITBCC scores in endometrial cancer.
From: Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups
Feature | HR (95% CI) | P value |
|---|---|---|
ITBCC | ||
No buds | 1.0 | 0.0329 |
Any buds | 2.0 (1.1–3.8) | |
T stage | ||
T1–2 | 1.0 | 0.0875 |
T3-4 | 2.16 (0.9–5.2) | |
N stage | ||
N0 | 1.0 | 0.0066 |
N1 | 3.13 (1.4–7.1) | |
M stage | ||
M0 | 1.0 | 0.0041 |
M1 | 3.9 (1.5–9.8) | |
L stage | ||
L0 | 1.0 | 0.654 |
L1 | 0.84 (0.4–1.8) | |
V stage | ||
V0 | 1.0 | 0.0936 |
V1 | 1.7 (0.9–3.36) | |
Grading | ||
G1–G2 | 1.0 | 0.7949 |
G3 | 1.06 (0.7–1.8 | |
